# Glucose Variability Analysis in Two Large-Scale and Real-World Data Sets of Open-Source Automated Insulin Delivery Systems

**Authors:** Drew Cooper, Bernd Reinhold, Arsalan Shahid, Dana M. Lewis

PMC · DOI: 10.1177/19322968231198871 · Journal of Diabetes Science and Technology · 2023-09-26

## TL;DR

This study analyzes glucose variability in real-world data from open-source automated insulin delivery systems, showing they meet recommended diabetes management goals.

## Contribution

The study provides new evidence on the real-world efficacy of open-source automated insulin delivery systems using two large datasets.

## Key findings

- Both datasets show glucose metrics within recommended goals, indicating effective diabetes management.
- Statistically significant differences in glucose variability metrics were found between the datasets.
- Gender differences were observed in low blood glucose index (LBGI) but not in high blood glucose index (HBGI).

## Abstract

Open-source automated insulin delivery (OS-AID) systems combine commercially available insulin pumps and continuous glucose monitors with open-source algorithms to automate insulin dosing for people with insulin-requiring diabetes. Two data sets (OPEN and the OpenAPS Data Commons) contain anonymized OS-AID user data.

We assessed glycemic variability (GV) outcomes in the OPEN data set and characterized it alongside a comparison to the n = 122 version of the OpenAPS Data Commons. Glucose data are analyzed using an unsupervised machine learning algorithm for clustering, and GV metrics are quantified using statistical tests for distribution comparison. Demographic data are also analyzed quantitatively.

The n = 75 OPEN data set contains 36 827 days worth of data. Mean TIR is 82.08% (TOR < 70: 3.66%; TOR > 180: 14.3%). LBGI (P < .05) differs by gender whereas HBGI distributions are similar (P > .05). GV metrics (except TOR < 70, LBGI) show a statistically significant difference (P < .05) between data sets.

Both the OPEN and OpenAPS Data Commons data sets show TOR < 70, TIR, and TOR > 180 within recommended goals, adding additional evidence of real-world efficacy of OS-AID. Future research should evaluate in more detail potential data set differences and relationships between individual patterns of user behaviors and GV outcomes.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Diseases:** diabetes (MESH:D003920), Insulin (MESH:D007333), OPEN (OMIM:606689)
- **Chemicals:** Glucose (MESH:D005947)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12035276/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12035276/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12035276/full.md

---
Source: https://tomesphere.com/paper/PMC12035276